MX2017009863A - Agente preventivo y/o terapeutico de enfermedad inmune. - Google Patents
Agente preventivo y/o terapeutico de enfermedad inmune.Info
- Publication number
- MX2017009863A MX2017009863A MX2017009863A MX2017009863A MX2017009863A MX 2017009863 A MX2017009863 A MX 2017009863A MX 2017009863 A MX2017009863 A MX 2017009863A MX 2017009863 A MX2017009863 A MX 2017009863A MX 2017009863 A MX2017009863 A MX 2017009863A
- Authority
- MX
- Mexico
- Prior art keywords
- prophylactic
- therapeutic agent
- immune diseases
- compound
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporciona un agente preventivo y/o terapéutico para enfermedades inmunes que contienen un compuesto que tiene una actividad inhibidora de BTK o una sal del mismo, como un ingrediente activo; un agente preventivo y/o terapéutico de enfermedades inmunes, que comprende un compuesto representado por la fórmula (I), donde R1 a R3, W, X, Y, Z, y n representan los definidos en la especificación, o una sal del mismo, como un ingrediente activo. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015017386 | 2015-01-30 | ||
| PCT/JP2016/052732 WO2016121953A1 (ja) | 2015-01-30 | 2016-01-29 | 免疫疾患の予防及び／又は治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017009863A true MX2017009863A (es) | 2017-11-15 |
Family
ID=56543555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009863A MX2017009863A (es) | 2015-01-30 | 2016-01-29 | Agente preventivo y/o terapeutico de enfermedad inmune. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9782412B2 (es) |
| EP (1) | EP3120852B1 (es) |
| JP (1) | JP6093485B2 (es) |
| KR (1) | KR101858421B1 (es) |
| CN (2) | CN113768935B (es) |
| AU (1) | AU2016213030B2 (es) |
| BR (1) | BR112017016278B1 (es) |
| CA (1) | CA2975372C (es) |
| DK (1) | DK3120852T3 (es) |
| ES (1) | ES2734364T3 (es) |
| HU (1) | HUE045532T2 (es) |
| MX (1) | MX2017009863A (es) |
| MY (1) | MY197518A (es) |
| PH (1) | PH12017501336A1 (es) |
| PL (1) | PL3120852T3 (es) |
| PT (1) | PT3120852T (es) |
| RU (1) | RU2705154C2 (es) |
| SG (1) | SG11201704430SA (es) |
| TR (1) | TR201910158T4 (es) |
| TW (1) | TWI638817B (es) |
| WO (1) | WO2016121953A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6093486B2 (ja) | 2015-01-30 | 2017-03-08 | 大鵬薬品工業株式会社 | 縮合ピリミジン化合物の新規な塩及びその結晶 |
| TW202135817A (zh) * | 2019-12-19 | 2021-10-01 | 日商大鵬藥品工業股份有限公司 | 以縮合嘧啶化合物作為有效成分之治療劑 |
| CN112209894B (zh) * | 2020-10-23 | 2023-06-06 | 贵州医科大学 | 5-芳基取代2-氨基苯并恶唑类衍生物、制备方法及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067781A2 (en) * | 2005-12-08 | 2007-06-14 | Abbott Laboratories | 9-membered heterobicyclic compounds as inhibitors of protein kinases |
| PT2073810E (pt) * | 2006-09-13 | 2011-09-30 | Takeda Pharmaceutical | Utilização de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo- 3,4-di-hidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo para tratamento de diabetes, cancro, distúrbios auto-imunes e infecção por vih |
| CA2668286C (en) * | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| JP2009235057A (ja) * | 2007-10-31 | 2009-10-15 | Santen Pharmaceut Co Ltd | 血管新生阻害活性を有する新規インドール誘導体 |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| CA2841080A1 (en) * | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2013108809A1 (ja) * | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | ３，５－二置換ベンゼンアルキニル化合物及びその塩 |
| JP2015526520A (ja) * | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体 |
| JP6035423B2 (ja) * | 2013-08-12 | 2016-11-30 | 大鵬薬品工業株式会社 | 新規な縮合ピリミジン化合物又はその塩 |
-
2016
- 2016-01-29 DK DK16743556.9T patent/DK3120852T3/da active
- 2016-01-29 CA CA2975372A patent/CA2975372C/en active Active
- 2016-01-29 BR BR112017016278-4A patent/BR112017016278B1/pt active IP Right Grant
- 2016-01-29 PL PL16743556T patent/PL3120852T3/pl unknown
- 2016-01-29 MY MYPI2017701813A patent/MY197518A/en unknown
- 2016-01-29 KR KR1020177018431A patent/KR101858421B1/ko active IP Right Grant
- 2016-01-29 JP JP2016533731A patent/JP6093485B2/ja active Active
- 2016-01-29 TW TW105102962A patent/TWI638817B/zh active
- 2016-01-29 EP EP16743556.9A patent/EP3120852B1/en active Active
- 2016-01-29 MX MX2017009863A patent/MX2017009863A/es unknown
- 2016-01-29 AU AU2016213030A patent/AU2016213030B2/en active Active
- 2016-01-29 CN CN202111054911.9A patent/CN113768935B/zh active Active
- 2016-01-29 WO PCT/JP2016/052732 patent/WO2016121953A1/ja active Application Filing
- 2016-01-29 HU HUE16743556A patent/HUE045532T2/hu unknown
- 2016-01-29 ES ES16743556T patent/ES2734364T3/es active Active
- 2016-01-29 SG SG11201704430SA patent/SG11201704430SA/en unknown
- 2016-01-29 CN CN201680007390.2A patent/CN107206001B/zh active Active
- 2016-01-29 PT PT16743556T patent/PT3120852T/pt unknown
- 2016-01-29 TR TR2019/10158T patent/TR201910158T4/tr unknown
- 2016-01-29 RU RU2017127126A patent/RU2705154C2/ru active
- 2016-10-19 US US15/297,196 patent/US9782412B2/en active Active
-
2017
- 2017-07-24 PH PH12017501336A patent/PH12017501336A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502363A1 (en) | Brk inhibitory compound | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EA201990833A1 (ru) | Соединение пиридина | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| PH12016501963A1 (en) | Macrocyclic pyrimidine derivatives | |
| PH12016501962A1 (en) | Macrocyclic pyridine derivatives | |
| AU2015211852A1 (en) | Heterocyclic sulfonamide derivative and medicine comprising same | |
| PH12017500737A1 (en) | Kcnq2-5 channel activator | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| MX2020005079A (es) | Derivados de aminotiazol utiles como agentes antiviricos. | |
| EA201790016A1 (ru) | АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K | |
| JO3372B1 (ar) | مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية | |
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| PH12017501336A1 (en) | Preventive and/or therapeutic agent of immune disease | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| AU2016248387A8 (en) | Preparation and use of kinase inhibitor | |
| WO2016072854A3 (en) | Pantothenamide analogues | |
| MX367576B (es) | Agente terapéutico o profiláctico para esclerosis múltiple. | |
| MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. |